Equity Profile

DXCM

DexCom, Inc.

Health CareHealth Care Equipment$29.5B

Apr30Thu

Post-Earnings Recap

ReportedQ1-2026After Close4:02 PM EDT

DexCom Beats on EPS, Stock Up 3.46%

Metric	Actual	Expected	Surprise
EPS	$0.56	$0.47	+19.66%
Revenue	N/A	$1.2B	N/A

management commentary, guidance changes, and full analysis available with Pro.

DexCom Beats on EPS, Stock Up 3.46%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.56	$0.47	+19.66%
Revenue	N/A	$1.2B	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

DexCom's strong earnings per share performance exceeded expectations, contributing to a positive stock reaction with a 3.46% increase. However, the lack of revenue data and management commentary leaves some uncertainty regarding the company's overall performance and future outlook.

Company Snapshot

DexCom, Inc. is a healthcare company that specializes in continuous glucose monitoring systems for people with diabetes....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and is closely watched by investors.

0.47

Revenue

Revenue figures help gauge the company's sales performance and market demand for its products.

1.2B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

DexCom, Inc. is a healthcare company that specializes in continuous glucose monitoring systems for people with diabetes. As a leader in health care equipment, its products play a crucial role in managing diabetes, a growing health concern worldwide.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+0.22%

Avg Stock Reaction

-0.38%

Last Quarter Recap

In Q4-2025, DexCom reported an EPS of $0.68, surpassing estimates by 4.62%. However, the stock fell 4.50% the following day, indicating market skepticism despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect DexCom to report earnings of $0.47 per share on $1.2 billion in revenue for Q1-2026. The market is closely watching how the company navigates ongoing competition and product demand.

Bull Case

If DexCom can exceed earnings expectations and show strong revenue growth, it may indicate robust demand for its glucose monitoring systems, potentially driving the stock higher.

Bear Case

Conversely, if the company misses earnings estimates or provides weak guidance, it could raise concerns about its market position and growth prospects, leading to a decline in stock price.

Key Metrics to Watch

EPS

0.47

Earnings per share is a key indicator of profitability and is closely watched by investors.

Revenue

1.2B

Revenue figures help gauge the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will DexCom's EPS exceed the consensus estimate of $0.47?

A strong earnings report could signal continued demand for its products and boost investor confidence.

What guidance will management provide regarding revenue growth for the upcoming quarters?

Guidance on future revenue is crucial for understanding the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating DexCom's ability to maintain its market position and revenue growth despite competitive pressures.

Supporting Evidence

DexCom has consistently beaten EPS estimates in the past quarters, indicating strong operational performance.

The options market is pricing in a significant move, suggesting that investors expect volatility that may not align with consensus expectations.

Key Risk

If management provides strong guidance on revenue growth, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether DexCom can sustain its growth amid increasing competition and evolving healthcare needs.

Bull Confirmed If

An EPS of $0.50 or higher would confirm strong operational performance and positive market sentiment.

Bear Confirmed If

An EPS below $0.42 would raise concerns about demand and competitive pressures in the market.

Pre-Earnings Positioning

Options Market

Implied Move

±10.92%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±10.9% while DXCM has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.9%

30d HV

32.9%

Calls (136K)P/C Ratio: 1.80Puts (203K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 7 of 23 (30%)

This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If DexCom beats expectations, history suggests a potential stock increase of around 1.67%, confirming strong demand and operational efficiency.

In-Line / Cautious

If the results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

Should the company miss earnings expectations, history suggests a potential decline of around 0.65%, reflecting investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

Senate only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-ARJohn BoozmanSen.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on new product launches or technological advancements.
2Updates on market share and competitive landscape.
3Insights into customer adoption rates for their glucose monitoring systems.
4Management's outlook on regulatory changes affecting the healthcare sector.
5Details on cost management strategies and their impact on margins.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

CDNSReported

Cadence Design Systems, Inc.

RecapView

Apr27

BRXReported

Company Snapshot

DexCom, Inc. is a healthcare company that specializes in continuous glucose monitoring systems for people with diabetes....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and is closely watched by investors.

0.47

Revenue

Revenue figures help gauge the company's sales performance and market demand for its products.

1.2B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+0.22%

Avg Stock Reaction

-0.38%

Last Quarter Recap

In Q4-2025, DexCom reported an EPS of $0.68, surpassing estimates by 4.62%. However, the stock fell 4.50% the following day, indicating market skepticism despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect DexCom to report earnings of $0.47 per share on $1.2 billion in revenue for Q1-2026. The market is closely watching how the company navigates ongoing competition and product demand.

Bull Case

If DexCom can exceed earnings expectations and show strong revenue growth, it may indicate robust demand for its glucose monitoring systems, potentially driving the stock higher.

Bear Case

Conversely, if the company misses earnings estimates or provides weak guidance, it could raise concerns about its market position and growth prospects, leading to a decline in stock price.

Key Metrics to Watch

EPS

0.47

Earnings per share is a key indicator of profitability and is closely watched by investors.

Revenue

1.2B

Revenue figures help gauge the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will DexCom's EPS exceed the consensus estimate of $0.47?

A strong earnings report could signal continued demand for its products and boost investor confidence.

What guidance will management provide regarding revenue growth for the upcoming quarters?

Guidance on future revenue is crucial for understanding the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating DexCom's ability to maintain its market position and revenue growth despite competitive pressures.

Supporting Evidence

DexCom has consistently beaten EPS estimates in the past quarters, indicating strong operational performance.

The options market is pricing in a significant move, suggesting that investors expect volatility that may not align with consensus expectations.

Key Risk

If management provides strong guidance on revenue growth, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether DexCom can sustain its growth amid increasing competition and evolving healthcare needs.

Bull Confirmed If

An EPS of $0.50 or higher would confirm strong operational performance and positive market sentiment.

Bear Confirmed If

An EPS below $0.42 would raise concerns about demand and competitive pressures in the market.

Pre-Earnings Positioning

Options Market

Implied Move

±10.92%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±10.9% while DXCM has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.9%

30d HV

32.9%

Calls (136K)P/C Ratio: 1.80Puts (203K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 7 of 23 (30%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If DexCom beats expectations, history suggests a potential stock increase of around 1.67%, confirming strong demand and operational efficiency.

In-Line / Cautious

If the results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

Should the company miss earnings expectations, history suggests a potential decline of around 0.65%, reflecting investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

Senate only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-ARJohn BoozmanSen.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on new product launches or technological advancements.
2Updates on market share and competitive landscape.
3Insights into customer adoption rates for their glucose monitoring systems.
4Management's outlook on regulatory changes affecting the healthcare sector.
5Details on cost management strategies and their impact on margins.